Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 10th January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

PetMedix and Zoetis to collaborate on antibody therapies
"Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets" - Robert J. Polzer, Zoetis.

Firms will use transgenic platforms for antibody discovery.

PetMedix has joined forces with Zoetis to develop new species-specific
animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms.

Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market.

Having already brought three novel mAbs to market, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies.

PetMedix chief executive Dr Tom Weaver commented: "We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination."

While many technologies have been used to develop human therapeutic antibodies, 40 years of research highlights the benefits of antibodies which are 100 per cent species-matched to the patient.

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms were developed in the same way as the leading human transgenic platforms. The collaboration also marks the third publicly-announced deal Zoetis has made with companies using transgenic platforms for antibody discovery.

Zoetis executive vice president and president Robert J. Polzer, said: "At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets."

Image (C) PetMedix.

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
RCVS pays tribute to well-loved equine vet

The RCVS and the Riding Establishments Subcommittee has paid tribute to well-loved veterinary surgeon and riding establishment inspector, Rebecca Hamilton-Fletcher MRCVS.

Linda Belton MRCVS, RCVS President, said: "I, along with my colleagues on the RESC, RCVS Council, RCVS Standards Committee, as well as RCVS staff, was very saddened to hear of the sudden death of Rebecca, or Becca as we knew her, last week.

"She was a true advocate for equine welfare and in her many years on the RESC worked to continually improve the quality and consistency of riding establishment inspections, all in the interests of enhanced horse welfare and rider safety."